Latest »
Eleventh Closed Scientific Expert Meeting of the Editorial Board
Is post-prandial lipaemia an independent risk factor for atherosclerosis?
Henry Ginsberg, Columbia University, New York, USA, addresses this question with results
of preclinical research into the potential atherogenicity of post-prandial lipoproteins, cohort data on the ability of fasting and non-fasting triglyceride levels to predict atherosclerotic cardiovascular disease (ASCVD), and long term follow up studies into associations between post-prandial lipoprotein measurements and future incident ASCVD events.
Watch the presentation
Adipose tissue-liver crosstalk: Implication of ANGPTL4 inhibition
Sander Kersten, Cornell University, New York, USA, considers the effects of liver- and adipose tissue-derived ANGPTL4 on lipoprotein lipase activity, together with the autocrine and endocrine roles of ANGPTL4 in plasma triglyceride regulation. He also reviews current understanding of the effects of ANGPTL4 silencing with antisense oligonucleotides in liver and adipose tissue and the impact on triglyceride levels.
Watch the presentation
Effects of omega-3 fatty acids, fibrates and PCSK9 inhibitors on plaque composition, burden and stability: Insights from imaging
Matthew Budoff, David Geffen School of Medicine at UCLA, Los Angeles, USA, compares imaging results showing the effects of current triglyceride-lowering therapies on plaque composition, stability and progression, and considers how these findings relate to results of key cardiovascular outcome trials with eicosapentaenoic acid/docosahexaenoic acid therapies, fibrates and PCSK9 inhibitors.
Watch the presentation
Setting the scene: In Phase 3 outcome trials with novel TG-lowering agents, which patient populations should we be targeting?
Ioanna Gouni-Berthold, University of Cologne, Germany, explains that previous cardiovascular outcomes trials (CVOTS) were performed in patients with moderate hypertriglyceridaemia (HTG) using agents that did not robustly reduce triglycerides or apoB, and she considers the rationale for CVOTs in secondary vs high risk primary prevention and moderate vs severe HTG using novel, stronger TG-lowering agents.
Watch the presentation
Update on novel apoC3-targeted therapeutics in hypertriglyceridaemia
Nicholas Marston, Brigham and Women’s Hospital, Boston, USA, provides a round-up of key data from clinical trials of apoC3-targeted agents that confirm their potential in the treatment of hypertriglyceridaemia, including reductions in acute pancreatitis and numbers needed to treat to achieve benefits, and he previews research into the effects of apoC3 inhibition on progression of coronary atherosclerosis.
Watch the presentation
Expert commentaries
Novel therapies in hypertriglyceridaemia: Trial results in 2025 and what’s to come in 2026
Dr
Nicholas Marston, Brigham and Women’s Hospital, Boston, USA, discusses progress in major clinical trials of emerging therapies targeting ANGPTL3, ANGPTL4 and apoC3 in a range of potential indications including familial chylomicronaemia syndrome, severe and moderate hypertriglyceridaemia and mixed dyslipidaemia, and looks forward to read-outs from studies that are scheduled for 2026.
Read the commentary
Metabolic fatty liver disease: How are triglycerides involved?
With metabolic fatty liver disease on the increase, Professor Robert Rosenson, Icahn School of Medicine at Mount Sinai, New York, USA, examines the link with triglycerides, discusses current treatment options and presents encouraging clinical trial data showing reduction in liver fat with novel triglyceride-lowering agents, with implications for future management of patients with this challenging condition.
Read the commentary
NEWS Updates
SHR-1918 shows promise in homozygous FH The ANGPTL3-targeting agent, SHR-1918, significantly reduced LDL-C, TG, apoB …
Fish oil supplements reduce serious CV events in patients on haemodialysis Patients undergoing maintenance haemodialysis …
2025: A Year of Progress in Triglyceride Research Over the past year, progress in the field of TG research has continued to gain momentum…
Redemplo (plozasiran) receives US approval for FCS The US Food and Drug Administration (FDA) has approved Redemplo (plozasiran) as an …
Third Closed Scientific Expert Meeting of the Editorial Board
Keynote: What have we learned from triglyceride lowering trials using fibrates over the past 40 years?
Professor Marja-Riitta Taskinen reviews the evidence from the FIELD and ACCORD clinical trials in type 2 diabetes and considers how treatment might be tailored to patients most likely to benefit.
Novel PPAR agonists as therapeutics in hypertriglyceridaemia
Professor Bart Staels discusses latest understanding of the mechanisms of action of PPAR agonists, together with pre-clinical and clinical data on the selective PPARα modulator, pemafibrate.
Expert Commentaries
Triglyceride-rich lipoproteins and their remnants: Commentary on the 2021 EAS Consensus Statement
Professor Gary Lewis (University of Toronto, Canada) discusses the evidence presented in the 2021 EAS Consensus Statement and its implications for clinicians and patients.
ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
Dr Michael Miller (University of Maryland, Baltimore, USA) discusses the background to the latest ACC guidance and the recommendation to stratify patients for treatment according to their residual LDL-cholesterol level.
Clinical trials of innovative therapeutics
New insights into the biology of triglyceride metabolism underpin the development of novel therapies for managing hypertriglyceridaemia to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and, for severely elevated levels, pancreatitis.
In the last decade epidemiology and genetic studies – in particular, Mendelian randomisation studies – have moved the field forward and we are on the cusp of a new era in managing elevated triglycerides.
Major outcomes studies with these new therapies are fundamental to answering the much-debated question: Does lowering elevated triglycerides reduce residual cardiovascular risk?
About Triglyceride Forum
The Triglyceride Forum is a unique, independent, expert-led global initiative to address the rapidly evolving field of triglycerides and triglyceride-rich lipoproteins in cardiovascular disease and pancreatitis. This Forum will provide clinicians and researchers with international, open access, peer-reviewed resources at an important time when new and innovative molecules are at advanced stages of development… Read more >>
Why join?
Professors Ginsberg and Chapman explain the fundamental scientific and clinical research that has turned the spotlight on triglyceride-rich lipoproteins and their remnants as important players in the development of atherosclerotic CVD and pancreatitis and as targets for novel therapies for both these serious diseases.
FREE MEMBERSHIP
Join the Triglyceride Forum for open access to independent, evidence based knowledge and high quality educational programmes
View invitation from Henry Ginsberg
Join the Triglyceride Forum to share new data and exchange opinions with clinicians and researchers around the world
View invitation from John Chapman
Meet our Steering Committee
Recommended Reading
Cholesterol, Lipoproteins, and Cardiovascular Health: Separating the Good (HDL), the Bad (LDL), and the Remnant.
Find out more about this thorough and rigorous new guide to the particles that are key to cardiovascular health …
Why triglycerides now?
From the editors
Educational partners and supporters
